CAR T-cell therapy is a potent investigational treatment used in patients with high tumor burden. A positive response to CAR T-cell therapy leads to difficult, but often reversible, side effects …
CAR T-Cell Therapy HCP Guide – Overview: Side Effects from CAR T-Cell Therapy Read More
December 1, 2016 (Blood) “Chimeric antigen receptors (CARs) are fusion proteins that combine antigen-recognition domains and T-cell signaling domains.” T cells harvested from patients’ blood and re-engineered to express CARs …
T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial Read More
June 21, 2016 (Medical News Today) In Phase 2 trials, chimeric antigen receptors (CARs), genetically engineered protein constructs, rewire T-cells in a patient’s own immune system to recognize and destroy …
CAR T-Cell Therapy Can Now Target Solid Tumors: Mouse Study Read More
To date in clinical trials, chimeric antigen receptor T (CAR-T) cell therapy has been used to treat which type of cancer? A. Sezary syndrome B. Chronic myeloid leukemia C. Mycosis …
StatPearls Question of the Week – #6 Read More
While CAR T-cell therapy in hematologic cancers is impressive, the fact remains that most deadly cancers are solid tumors like lung, breast, or colon cancer. Efforts are ongoing to understand …
CAR T-Cell Therapy HCP Guide – Solid Tumor Research: Progress to Be Made Read More
Aggressive B Cell Non-Hodgkin Lymphomas About 90% of lymphoma cases start in the B cells. The C19 tumor target that is sought by the CAR T cell therapy is found …
CAR T-Cell Therapy HCP Guide – Pivotal Trial: Aggressive B-Cell Non-Hodgkin Lymphoma Read More
Gene Therapy to the Rescue The first investigational oncology gene therapy known as a chimeric antigen receptor (CAR) T-cell therapy is rapidly moving towards FDA approval. These agents — by …
CAR T-Cell Therapy HCP Guide – Cancer Targets Read More
March 1, 2017 (The Scientist) In the 6-month follow-up for a Phase 2 trial focused on 101 advanced non-Hodgkin lymphoma patients who underwent chimeric antigen receptor T-cell (CAR-T) therapy, 41 …
Kite’s CAR T-Cell Therapy Success Read More
Many researchers, oncologists, and pharmaceutical companies hail CAR-T therapy as a “cure for cancer.” But what exactly is this evolving technology? How is it expected to revolutionize oncology? Here are …
14 scientific definitions for a deeper understanding of CAR-T therapy Read More
October 17, 2016 (CNBC) Arie Belldegrun, Kite Pharma CEO talks to CNBC’s Meg Tirrell about developing cancer immunotherapy drugs with T-cells. Also Belldegrun address the question about pricing the product …
VIDEO: Interview with Arie Belldegrun, Kite Pharma CEO on pricing Read More